Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 14
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Birger, Ruthie Kouyos, Roger Dushoff, Jonathan and Grenfell, Bryan 2015. Modeling the effect of HIV coinfection on clearance and sustained virologic response during treatment for hepatitis C virus. Epidemics, Vol. 12, p. 1.

    Manna, Kalyan and Chakrabarty, Siddhartha P. 2015. Chronic hepatitis B infection and HBV DNA-containing capsids: Modeling and analysis. Communications in Nonlinear Science and Numerical Simulation, Vol. 22, Issue. 1-3, p. 383.

    Gupta, P. Liu, B. Wu, J.Q. Soriano, V. Vispo, E. Carroll, A.P. Goldie, B.J. Cairns, M.J. and Saksena, N.K. 2014. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. Virology, Vol. 450-451, p. 336.

    Chun, Helen M. Carpenter, Robert J. Macalino, Grace E. and Crum-Cianflone, Nancy F. 2013. The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. Journal of Sexually Transmitted Diseases, Vol. 2013, p. 1.

    Fainboim, H. and Dirchwolf, M. 2013. Update on HIV and Hepatitis Virus Coinfection: The South American Perspective. Current Hepatitis Reports, Vol. 12, Issue. 4, p. 312.

    Chakrabarty, Siddhartha P. and Murray, John M. 2012. Modelling hepatitis C virus infection and the development of hepatocellular carcinoma. Journal of Theoretical Biology, Vol. 305, p. 24.

    Pachpute, Gaurav and Chakrabarty, Siddhartha P. 2012. Analysis of hepatitis C viral dynamics using Latin hypercube sampling. Communications in Nonlinear Science and Numerical Simulation, Vol. 17, Issue. 12, p. 5125.

    Zhang, Xiaozhen Daucher, Marybeth Baeza, Josue Kim, Cheol-Woo Russell, Rodney and Kottilil, Shyamasundaran 2012. Human immunodeficiency virus enhances hepatitis C virus replication by differential regulation of IFN and TGF family genes. Journal of Medical Virology, Vol. 84, Issue. 9, p. 1344.

    Operskalski, Eva A. and Kovacs, Andrea 2011. HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies. Current HIV/AIDS Reports, Vol. 8, Issue. 1, p. 12.

    Birerdinc, A. Afendy, A. Stepanova, M. Younossi, I. Manyam, G. Baranova, A. and Younossi, Z. M. 2010. Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. Journal of Viral Hepatitis, Vol. 17, Issue. 10, p. 730.

    Hiura, Masaaki Onizuka, Ryo Narita, Ryoichi Abe, Shintaro Tabaru, Akinari and Harada, Masaru 2010. A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy. Clinical Journal of Gastroenterology, Vol. 3, Issue. 5, p. 254.

    Moretti, Franco Bolcic, Federico Mammana, Lilia Bouzas, Maria Belen Laufer, Natalia and Quarleri, Jorge 2010. The Hepatitis C Virus 5′UTR Genomic Region Remains Highly Conserved Under HAART: A 4- to 8-Year Longitudinal Study from HCV/HIV Co-Infected Patients. AIDS Research and Human Retroviruses, Vol. 26, Issue. 5, p. 527.

    Singer, Merrill 2010. Pathogen-pathogen interaction. Virulence, Vol. 1, Issue. 1, p. 10.

    Ng, Siew C. and Gazzard, Brian 2009. Advances in sexually transmitted infections of the gastrointestinal tract. Nature Reviews Gastroenterology & Hepatology, Vol. 6, Issue. 10, p. 592.

  • Expert Reviews in Molecular Medicine, Volume 10
  • 2008, e30

Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus

  • Barbara Roe (a1) and William W. Hall (a1)
  • DOI:
  • Published online: 20 October 2008

Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) is associated with increased HCV replication and a more rapid progression to severe liver disease, including the development of cirrhosis and hepatocellular carcinoma. In this review, we discuss the current understanding of the pathogenesis of HCV/HIV coinfection and the cellular and molecular mechanisms associated with the accelerated course of liver disease. The strength and breadth of HCV-specific T-cell responses are reduced in HCV/HIV-coinfected patients compared with those infected with HCV alone, suggesting that the immunosuppression induced by HIV compromises immune responses to HCV. HCV is not directly cytopathic, but many of the pathological changes observed in the liver of infected patients are a direct result of the intrahepatic antiviral immune responses. Apoptosis also has a role in HCV-mediated liver damage through the induction of apoptotic pathways involving the host immune response and HCV viral proteins. This review summarises the evidence correlating the role of cell-mediated immune responses and apoptosis with liver disease progression in HCV/HIV-coinfected patients.

Corresponding author
*Corresponding Author: William W. Hall, Centre for Research in Infectious Diseases, University College Dublin, Belfield, Dublin 4, Ireland; Tel: +353 1 7161236; Fax: +353  1 7161239; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1J.M. Pawlotsky (2004) Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 12, 96-102

3K.D. Palitzsch (1999) Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 11, 1215-1220

4D.J. Mutimer (1995) Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepat 2, 47-53

5C. Meffre (2006) Prevalence of hepatitis B and hepatitis C in France, 2004. Journal of Clinical Virology 36 (Suppl 2), S197

6G.L. Armstrong (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144, 705-714

9G. Xia (1996) Prevalence of Hepatitis B and C Virus Infections in the General Chinese Population. Results from a Nationwide Cross-sectional Seroepidemiologic Study of Hepatitis A, B, C, D, and E Virus Infections in China, 1992. International Hepatology Communications 5, 62-73

10C. Frank (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887-891

11M. Schmeding (2007) Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 13, 687-692

13R. Jones , J. Dunning and M. Nelson (2005) HIV and hepatitis C coinfection. Int J Clin Pract 59, 1082-1087

14M.S. Sulkowski and D.L. Thomas (2003) Hepatitis C in the HIV-Infected Person. Ann Intern Med 138, 197-207

15L.B. Seeff (2002) Natural history of chronic hepatitis C. Hepatology 36 (Suppl 1), S35-46

16J. Garcia-Samaniego (2001) Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 96, 179-183

17B. Soto (1997) Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26, 1-5

18F.J. Palella Jr. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338, 853-860

20B. Robertson (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143, 2493-2503

21M. Kaito (1994) Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 75, 1755-1760

26S.D. Griffin (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535, 34-38

27D. Pavlovic (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 100, 6104-6108

28E. Steinmann (2007) Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. PLoS Pathog 3, e103

29A. Grakoui (1993) A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A 90, 10583-10587

30B.D. Lindenbach and C.M. Rice (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436, 933-938

32M. Elazar (2004) An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol 78, 11393-11400

33D. Egger (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76, 5974-5984

34S.L. Tan and M.G. Katze (2001) How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284, 1-12

37A.D. Frankel and J.A. Young (1998) HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67, 1-25

38A.C. Hearps and D.A. Jans (2007) Regulating the functions of the HIV-1 matrix protein. AIDS Res Hum Retroviruses 23, 341-346

40M. Hill , G. Tachedjian and J. Mak (2005) The packaging and maturation of the HIV-1 Pol proteins. Curr HIV Res 3, 73-85

41S.K. Arya (1985) Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229, 69-73

42A.G. Fisher (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320, 367-371

43B.K. Felber (1989) rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci U S A 86, 1495-1499

44J.V. Garcia and A.D. Miller (1992) Downregulation of cell surface CD4 by nef. Res Virol 143, 52-55

46N.K. Heinzinger (1994) The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 91, 7311-7315

47G. Greub (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356, 1800-1805

48A. De Luca (2002) Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 162, 2125-2132

49L. Piroth (2000) Hepatitis C virus coinfection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 7, 302-308

50J.K. Rockstroh (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192, 992-1002

51M.S. Sulkowski (2002) Hepatitis C and progression of HIV disease. J Am Med Ass 288, 199-206

52M. Bonacini (2004) Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. Aids 18, 2039-2045

53M. Dorrucci (1995) Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 172, 1503-1508

54D. Lincoln , K. Petoumenos and G.J. Dore (2003) HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 4, 241-249

55C.T. Staples Jr, D. Rimland and D. Dudas (1999) Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS, the effect of coinfection on survival. Clin Infect Dis 29, 150-154

56D.C. Melvin (2000) The impact of coinfection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. Aids 14, 463-465

57M.S. Sulkowski (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35, 182-189

58M. Bonacini (1999) Patients coinfected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 6, 203-208

60E.S. Daar (2001) Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 26, 466-472

62S.J. Hadziyannis (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140, 346-355

63M.P. Manns (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965

64F. Carrat (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J Am Med Ass 292, 2839-2848

65R.T. Chung (2004) Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351, 451-459

66F.J. Torriani (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351, 438-450

67M. Nunez (2007) Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 23, 972-982

68Y. Benhamou (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30, 1054-1058

69P.W. Canchis (2004) Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 37, 1125-1131

70N. Brau (2006) Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44, 47-55

71N. Qurishi (2003) Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362, 1708-1713

72H.M. Diepolder (1995) Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346, 1006-1007

73F. Lechner (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191, 1499-1512

74H. Wedemeyer (2002) Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169, 3447-3458

75A. Grakoui (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659-662

76N.H. Shoukry (2003) Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197, 1645-1655

77D.J. Shedlock and H. Shen (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339

78J.T. Gerlach (1999) Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117, 933-941

79S.L. Tsai (1997) Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25, 449-458

80K. Bjoro (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331, 1607-1611

81K.M. Chang (1997) Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100, 2376-2385

83A.L. Erickson (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883-895

84J. Timm (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200(12), 1593-604

85A. Weiner (1995) Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 92, 2755-2759

86R. Thimme (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395-1406

87C. Bain (2001) Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120, 512-524

88M.T. Brady (2003) Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol 33, 3448-3457

89A. Dolganiuc (2003) Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 170, 5615-5624

90O. Disson (2004) Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 126, 859-872

91L. Frelin (2006) The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor {alpha} mediated liver disease. Gut 55, 1475-1483

92L. Capa (2007) Influence of HCV genotype and coinfection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 79, 503-510

93V. Dutoit (2005) Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV coinfection. Eur J Immunol 35, 3493-3504

94C.S. Graham (2004) Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 40, 125-132

95H. Valdez (2000) Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. Aids 14, 2239-2246

96C.S. Graham (2005) Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. Aids 19, 767-773

97D.M. Brainard (2007) Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J Virol 81, 8439-8450

98H.F. Lohr (1998) The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. J Hepatol 29, 524-532

99D.L. Thomas (2006) Options for treatment of hepatitis C in HIV-infected persons. J Hepatol 44 (Suppl.) S40-43

101C.T. Tseng (2001) Characterization of liver T-cell receptor gammadelta T cells obtained from individuals chronically infected with hepatitis C virus (HCV, evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 33, 1312-1320

102P.M. Jacobson Brown and M.G. Neuman (2001) Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 34, 167-171

103G. Alkhatib (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958

104Y. Feng (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877

105C.H. Kim (2001) Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108, 1331-1339

106F. Sallusto (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187, 875-883

107A. Apolinario (2002) Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 97, 2861-2870

109D.D. Taub (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177, 1809-1814

110D. Butera (2005) Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106, 1175-1182

111S. Mihm , S. Schweyer and G. Ramadori (2003) Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol 70, 562-570

112C.E. Harvey (2003) Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 74, 360-369

113A.I. Romero (2006) Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 194, 895-903

114M. Diago (2006) Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55, 374-379

115P. Cinque (2005) Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 168, 154-163

116E. Stylianou (2000) Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 119, 479-485

117B.R. Lane (2003) The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 307, 122-134

118B. Roe (2007) Elevated Serum Levels of Interferon-gamma-Inducible Protein-10 in Patients Coinfected with Hepatitis C Virus and HIV. J Infect Dis 196, 1053-1057

119A. Balasubramanian , R.K. Ganju and J.E. Groopman (2003) Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem 278, 35755-35766

120T. Kuntzen (2008) Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus coinfection: infiltrating cells, cytokines, and influence of HAART. Aids 22, 203-210

121F. Farinati (2006) Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol 12, 2065-2069

122A.R. Zekri (2005) Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol 11, 6624-6630

124J.M. Molina (1989) Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 84, 733-737

125T.M. Folks (1989) Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86, 2365-2368

126G. Poli (1990) Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 172, 151-158

127G. Poli , A.L. Kinter and A.S. Fauci (1994) Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A 91, 108-112

128I. Abbate (2004) Intra-hepatic messenger RNA levels for interferons and related genes in hepatitis C virus/HIV coinfected patients. Aids 18, 691-692

129J.T. Blackard (2006) Intrahepatic cytokine expression is downregulated during HCV/HIV coinfection. J Med Virol 78, 202-207

130S.A. Gonzalez (2007) Hepatic inflammatory cytokine mRNA expression in hepatitis C virus-human immunodeficiency virus coinfection. J Viral Hepat 15, 331-338

132M.E. Guicciardi and G.J. Gores (2005) Apoptosis: a mechanism of acute and chronic liver injury. Gut 54, 1024-1033

133Z. Jin and W.S. El-Deiry (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4, 139-163

134S.K. Rupinder , A.K. Gurpreet and S. Manjeet (2007) Cell suicide and caspases. Vascul Pharmacol 46, 383-393

135S.J. Riedl and G.S. Salvesen (2007) The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8, 405-413

136H. Bantel (2001) Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34, 758-767

137H. Bantel (2001) Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 80, 230-239

138F. Calabrese (2000) Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31, 1153-1159

140G. Kunstle (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Immunol Lett 55, 5-10

141N. Rouquet (1996) ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 6, 1192-1195

142A.H. Chou (2005) Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 174, 2160-2166

143M. Okuda (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122, 366-375

144M. Otsuka (2002) Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-xL expression. Virology 296, 84-93

145R.B. Ray (1998) Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 273, 2256-2259

146E.A. Prikhod'ko (2004) The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 329, 53-67

147E. Meylan (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172

148Y.L. Chung , M.L. Sheu and S.H. Yen (2003) Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 107, 65-73

149J. Wang (2006) Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett 580, 4392-4400

150K.H. Lan (2002) HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 21, 4801-4811

151G. Gong (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98, 9599-9604

152A. Street (2004) The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 279, 12232-12241

153S. Siavoshian (2005) Hepatitis C virus core, NS 3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells. J Med Virol 75, 402-411

154N. Munshi (2003) Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 188, 1192-1204

155A. Balasubramanian (2005) Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 41 (Suppl. 1), S32-37

156A. Balasubramanian , R.K. Ganju and J.E. Groopman (2006) Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis 194, 670-681

157J. Macias (2005) Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 192, 1566-1576

158B. Autran (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116

159O. Pontesilli (1999) Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 66, 213-217

160J.C. Tilton (2007) Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 81, 2713-2725

161P.J. Pockros (2007) Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46, 324-329

H. Malhi and G.J. Gores (2008) Cellular and Molecular Mechanisms of Liver Injury. Gastroenterology 134, 1641-1654

P. Klenerman and A. Kim (2007) HCV-HIV Coinfection: Simple Messages from a Complex Disease. PLoS Med 4, 1608-1614

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *